- Home
- TNXP vs PYPD Comparison
TNXP vs PYPD Comparison
Compare TNXP & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNXP
- PYPD
- Stock Information
- Founded
- TNXP 2007
- PYPD 2008
- Country
- TNXP United States
- PYPD Israel
- Employees
- TNXP N/A
- PYPD N/A
- Industry
- TNXP Biotechnology: Pharmaceutical Preparations
- PYPD Medical/Dental Instruments
- Sector
- TNXP Health Care
- PYPD Health Care
- Exchange
- TNXP Nasdaq
- PYPD Nasdaq
- Market Cap
- TNXP 15.1M
- PYPD 16.3M
- IPO Year
- TNXP N/A
- PYPD 2020
- Fundamental
- Price
- TNXP $0.14
- PYPD $3.59
- Analyst Decision
- TNXP Strong Buy
- PYPD Buy
- Analyst Count
- TNXP 2
- PYPD 2
- Target Price
- TNXP $53.50
- PYPD $12.00
- AVG Volume (30 Days)
- TNXP 35.7M
- PYPD 4.6K
- Earning Date
- TNXP 11-07-2024
- PYPD 11-06-2024
- Dividend Yield
- TNXP N/A
- PYPD N/A
- EPS Growth
- TNXP N/A
- PYPD N/A
- EPS
- TNXP N/A
- PYPD N/A
- Revenue
- TNXP $12,458,000.00
- PYPD N/A
- Revenue This Year
- TNXP $62.53
- PYPD N/A
- Revenue Next Year
- TNXP $26.17
- PYPD N/A
- P/E Ratio
- TNXP N/A
- PYPD N/A
- Revenue Growth
- TNXP N/A
- PYPD N/A
- 52 Week Low
- TNXP $0.12
- PYPD $2.95
- 52 Week High
- TNXP $22.08
- PYPD $9.20
- Technical
- Relative Strength Index (RSI)
- TNXP 29.54
- PYPD 52.68
- Support Level
- TNXP $0.12
- PYPD $3.31
- Resistance Level
- TNXP $0.21
- PYPD $3.75
- Average True Range (ATR)
- TNXP 0.02
- PYPD 0.20
- MACD
- TNXP 0.02
- PYPD 0.01
- Stochastic Oscillator
- TNXP 21.56
- PYPD 61.25
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.